Log in to save to my catalogue

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor...

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pnas_primary_110_32_E2987

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

About this item

Full title

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

Publisher

United States: National Academy of Sciences

Journal title

Proceedings of the National Academy of Sciences - PNAS, 2013-08, Vol.110 (32), p.E2987-E2996

Language

English

Formats

Publication information

Publisher

United States: National Academy of Sciences

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Binding of hepatocyte growth factor (HGF) to the receptor tyrosine kinase MET is implicated in the malignant process of multiple cancers, making disruption of this interaction a promising therapeutic strategy. However, targeting MET with bivalent antibodies can mimic HGF agonism via receptor dimerization. To address this limitation, we have develop...

Alternative Titles

Full title

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pnas_primary_110_32_E2987

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pnas_primary_110_32_E2987

Other Identifiers

ISSN

0027-8424

E-ISSN

1091-6490

DOI

10.1073/pnas.1302725110

How to access this item